Get notified of page updates

BRCA2: Options for Managing Risk

Learn about the screening and prevention guidelines for people with a mutation in their BRCA2 gene. Stay up to date by signing up for our community newsletter.
Glossary on
off

Risk Management for People with Inherited Mutations

People with  mutations have options for managing their increased cancer risk. Experts at the National Comprehensive Cancer Network (NCCN) created guidelines for people with a mutation to manage their cancer risk.

We recommend that you speak with a genetics expert who can look at your personal and family history of cancer and can help you decide on a plan for managing your risk. Note that when we use "female" and "male" or "women" and "men" we are referring to the sex you were assigned at birth.

NCCN recommends that all people with an inherited mutation receive education on the signs and symptoms of BRCA2-related cancers. NCCN guidelines for specific cancers are listed below. 


People with a  mutation may also qualify for clinical trials looking for more effective screening or prevention for cancer.

In the News

Ovary removal reduces risk of death from any cause in people with BRCA mutations

Study : Ovary removal reduces risk of death from any cause in people with BRCA mutations

People who test positive for an inherited BRCA1 or BRCA2 mutation can reduce their risk of ovarian cancer by having both ovaries and fallopian tubes removed. A study published in 2024 found an added benefit...


Breast cancer risk management for women and people assigned female at birth

Beginning Age

Recommendation

Additional Information

18

Learn to be aware of changes in your breasts.

25

Breast exam by doctor every 6-12 months.

25 (or younger based on family history)

Yearly breast MRI with and without contrast beginning at age 25 and continuing until age 75.

If MRI is not available, mammogram screening should begin at age 25.

30

Yearly mammogram.

No set age

Discuss the benefits, risks and costs of double mastectomy with your doctor.

Risk-reducing mastectomy lowers breast cancer risk by 90%, but has not been shown to improve survival. Even after double mastectomy, some breast tissue, and therefore cancer risk remains.

No set age

Discuss the benefits, risks and costs of medications to lower the risk for breast cancer with your doctor.

Tamoxifen or other estrogen-blocking drugs lower breast cancer risk. Medications or vaccines are being studied in clinical trials.

75

Consider whether to continue, stop or change breast screening.

Source: NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, vs. 1 2025.

Breast cancer risk management for men and people assigned male at birth

Beginning Age

Recommendation

35

Learn how to do a breast self-exam and be aware of changes in your breasts.

35

Breast exam by doctor every 6-12 months.

50 (or earlier based on the youngest case of male breast cancer in the family)

Have a discussion with your doctor about the benefits, risks and costs of annual mammograms.

Source: NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, vs. 1 2025.


Risk management for gynecologic cancer 

Beginning Age

Recommendation

Additional Information

40-45 (or earlier based on the youngest case of ovarian cancer in the family)

Risk-reducing removal of ovaries and fallopian tubes (RRSO). Timing of surgery should take into account plans to have children.

  • Salpingo-oophorectomy in people with BRCA mutations has been linked to longer survival compared to people who have not had surgery.
  • The surgery should be done at a facility that has expertise and follows special precautions for people with inherited mutations. This includes a procedure known as an abdominal wash at the time of surgery. The pathologist should do an extensive exam of the fallopian tubes using a procedure called SEE-FIM to look for any abnormal changes in the tissue.
  • If an abnormality known as a "serous tubal intraepithelial carcinoma" or STIC lesion is noted in your pathology report, you should be referred to a gynecologic oncologist for follow up care.
  • Discuss options for managing the effects of early menopause with your doctor.
  • After RRSO, a very small risk remains for a related cancer known as primary peritoneal cancer (PPC). There is no effective screening for PPC after RRSO.

40-45

Have a discussion with your doctor about the risks, benefits and costs of removing your uterus (hysterectomy) at the time of RRSO.

The following factors may affect your decision about hysterectomy at the time of RRSO:

  • BRCA2 mutations may slightly increase the risk for a rare but aggressive type of uterine cancer.
  • If you have a medical history of fibroids or other issues involving the uterus or cervix you might consider a hysterectomy.
  • If you are considering hormone replacement, the type of hormone recommended depends on whether or not you have your uterus.
    • Estrogen alone increases the risk for uterine cancer.
    • Estrogen combined with progesterone protects against uterine cancer, but is linked to a higher risk for breast cancer than estrogen alone.

Before age 50

Experts believe that most ovarian cancers begin in the fallopian tubes. Researchers are studying whether the removal of the fallopian tubes only (salpingectomy), while delaying oophorectomy until closer to the age of natural menopause is a safe option for lowering risk in people who are not ready to remove their ovaries. Guidelines recommend that people interested in this approach speak with their doctor about the benefits and risks, and consider enrolling in a research study.

  • At this time, it is not known if salpingectomy is effective for lowering the ovarian cancer risk in high-risk people.
  • For this reason, experts recommend that people who choose salpingectomy have a completion oophorectomy to lower their remaining risk for ovarian cancer when they are ready.
  • Salpingectomy, followed by delayed oophorectomy requires two separate surgeries.

No set age

Speak with your doctor about the benefits, risks and timing of oral contraceptives or progestin intrauterine devices (IUD) to lower the risk for ovarian and fallopian tube cancers.

  • Oral contraceptives (birth control pills) have been shown to lower the risk for ovarian cancer in people with BRCA mutations.
  • Progestin intrauterine devices (IUD) may also lower the risk for ovarian cancer in people with BRCA mutations.
  • Research on the affect of oral contraceptives on breast cancer risk has been mixed.

No set age

Become aware of ovarian and primary peritoneal cancer symptoms. Report to any symptoms that persist for several weeks and are a change from normal to your doctor.

Routine ovarian cancer screening using transvaginal ultrasound and a CA-125 blood test has not shown benefit and is not recommended.

Symptoms of ovarian cancer include:

  • pelvic or abdominal pain
  • bloating or distended belly
  • difficulty eating
  • feeling full sooner than normal
  • increased urination or pressure to urinate

Source: NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, vs. 1 2025.


Risk management for cancer 

Beginning Age

Recommendation

40

Annual digital rectal exam and Prostate Specific Antigen (PSA) test.

Source: NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, vs. 1 2025.


Risk management for pancreatic cancer

There are two tests that are used to look for pancreatic cancer in high-risk people. 

  • MRCP (Contrast-enhanced magnetic resonance cholangiopancreatography) is a special type of  imaging that looks closely at the pancreas, liver, gallbladder, bile duct and pancreatic duct to find abnormalities such as cancer.
  • EUS (Endoscopic ) involves passing a tiny scope with an attached  probe down the esophagus to the stomach. This allows doctors to look closely at the pancreas.  

There are two separate organizations with guidelines related to screening for pancreatic cancer in people with  mutations, the American Society of Gastrointestinal Endoscopy (ASGE) and the National Comprehensive Cancer Network (NCCN). In the 2025 NCCN guidelines published in September 2024, the NCCN panel removed the family history requirement from the guidelines for people with mutations. 

Organization

Beginning Age

Family History

Recommendation

ASGE

50 (or earlier based on the youngest case of pancreatic cancer in the family)

For BRCA2 mutation carriers regardless of family history of pancreatic cancer

Annual screening for pancreatic cancer with MRI/MRCP or EUS

NCCN

50 (or earlier based on the youngest case of pancreatic cancer in the family)

For BRCA2 mutation carriers regardless of family history of pancreatic cancer

  • Discuss the benefits, risks, costs and limitations of screening with your doctor.
  • Screening should include annual MRCP or EUS or both.
  • Screening should be performed in a facility with experience in screening high-risk patients for pancreatic cancer.

Source: NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, vs. 1 2025; ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022 May;95(5):817-826. doi: 10.1016/j.gie.2021.12.001. Epub 2022 Feb 16. PMID: 35183358.


Other cancers

Melanoma 

NCCN does not include guidelines for melanoma screening for people with mutations. However, some experts recommend general melanoma risk management such as a yearly full-body skin exam, a yearly eye exam and avoiding too much sun exposure.

Other cancer screening and prevention

There has not been enough research to show a benefit from screening and prevention for other cancers in people who have a mutation. For this reason, experts recommend managing these risks based on your family history. Cancer screening and prevention research studies may be available.


Participate in Prevention Research

Below are some of our featured research studies looking at new ways to screen for, prevent or intercept cancer in people with mutations. To search for additional studies, visit our Search and Enroll Tool


Last updated September 17, 2024